Who
Susannah Gray
Director
Company insider
Files Form 4 as: Director, Theravance Biopharma; Director, 4D Molecular Therapeutics; Director, Maravai LifeSciences Holdings; Director, AnaptysBio; Director, Morphic Holding; Director, Apria.
In numbers
- Trades disclosed
- 58
- Buys
- 1
- Sells
- 0
- Bought
- $540K
- Sold
- $0
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 19 Nov 2020
- Last trade
- 23 Sep 2026
- Last filed
- 24 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —42,137 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —6,009 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —32,666 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —32,666 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —22,044 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —23,576 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —24,258 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —13,398 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —22,044 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —23,576 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —24,258 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —13,398 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —42,137 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —6,009 | filing |
| 17 Jun 2026filed 18 Jun 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code A | —6,009 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —13,398 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —13,398 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code A | —6,009 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.